Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHN702 in moderate to severe post-operative pain
NCT07277933Phase 1Not yet recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in postoperative pain comparing KHN702 with KHN702 placebo (2 arms). Primary endpoint: Time-weighted Sum of Pain Intensity Differences 0 to 48 hours. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
KHN702
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07277933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277933.